SK283484B6 - Spiroazabicyklické heterocyklické zlúčeniny, postupy a medziprodukty na ich prípravu, farmaceutické kompozície s ich obsahom a ich použitie - Google Patents

Spiroazabicyklické heterocyklické zlúčeniny, postupy a medziprodukty na ich prípravu, farmaceutické kompozície s ich obsahom a ich použitie Download PDF

Info

Publication number
SK283484B6
SK283484B6 SK1835-99A SK183599A SK283484B6 SK 283484 B6 SK283484 B6 SK 283484B6 SK 183599 A SK183599 A SK 183599A SK 283484 B6 SK283484 B6 SK 283484B6
Authority
SK
Slovakia
Prior art keywords
azabicyclo
octane
furo
pyridine
spiro
Prior art date
Application number
SK1835-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK183599A3 (en
Inventor
Eifion Phillips
Robert Mack
John Macor
Simon Semus
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9702746A external-priority patent/SE9702746D0/xx
Priority claimed from SE9800977A external-priority patent/SE9800977D0/xx
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of SK183599A3 publication Critical patent/SK183599A3/sk
Publication of SK283484B6 publication Critical patent/SK283484B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SK1835-99A 1997-07-18 1998-07-10 Spiroazabicyklické heterocyklické zlúčeniny, postupy a medziprodukty na ich prípravu, farmaceutické kompozície s ich obsahom a ich použitie SK283484B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9702746A SE9702746D0 (sv) 1997-07-18 1997-07-18 New compounds
SE9800977A SE9800977D0 (sv) 1998-03-24 1998-03-24 New compounds
PCT/SE1998/001364 WO1999003859A1 (en) 1997-07-18 1998-07-10 Novel spiroazabicyclic heterocyclic compounds

Publications (2)

Publication Number Publication Date
SK183599A3 SK183599A3 (en) 2000-08-14
SK283484B6 true SK283484B6 (sk) 2003-08-05

Family

ID=26663041

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1835-99A SK283484B6 (sk) 1997-07-18 1998-07-10 Spiroazabicyklické heterocyklické zlúčeniny, postupy a medziprodukty na ich prípravu, farmaceutické kompozície s ich obsahom a ich použitie

Country Status (31)

Country Link
US (6) US6110914A (zh)
EP (2) EP0996622B1 (zh)
JP (1) JP2001510194A (zh)
KR (1) KR100560036B1 (zh)
CN (1) CN1117755C (zh)
AR (2) AR013184A1 (zh)
AT (2) ATE225792T1 (zh)
AU (1) AU739022B2 (zh)
BR (1) BR9810924A (zh)
CA (1) CA2296031C (zh)
DE (2) DE69808631T2 (zh)
DK (1) DK0996622T3 (zh)
EE (1) EE04399B1 (zh)
ES (2) ES2231599T3 (zh)
HK (3) HK1025322A1 (zh)
HU (1) HUP0003844A3 (zh)
ID (1) ID25548A (zh)
IL (2) IL134086A0 (zh)
IS (2) IS2027B (zh)
MY (1) MY116761A (zh)
NO (1) NO325324B1 (zh)
NZ (1) NZ502298A (zh)
PL (1) PL193065B1 (zh)
PT (1) PT996622E (zh)
RU (1) RU2202553C2 (zh)
SA (1) SA98190668B1 (zh)
SI (1) SI0996622T1 (zh)
SK (1) SK283484B6 (zh)
TR (1) TR200000129T2 (zh)
TW (1) TW515799B (zh)
WO (1) WO1999003859A1 (zh)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ500643A (en) 1997-05-30 2001-12-21 Neurosearch As Spiro-quinuclidine derivatives and their use in treating conditions responsive to nicotinic ACh receptor modulators
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
US6277870B1 (en) * 1998-05-04 2001-08-21 Astra Ab Use
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds
FR2790474B1 (fr) * 1999-03-05 2001-04-06 Synthelabo Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
TWI298068B (en) * 2000-06-21 2008-06-21 Dainippon Sumitomo Pharma Co Pharmaceutical composition for schizophrenia
US6569865B2 (en) 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
IL158735A0 (en) * 2001-06-01 2004-05-12 Astrazeneca Ab Novel ligand for nicotinic acetylcholine receptors useful in therapy
AU2002339810A1 (en) * 2001-10-16 2003-04-28 Astrazeneca Ab Azabicyclic compounds for the treatment of fibromyalgia syndrome
US7067261B2 (en) * 2001-12-14 2006-06-27 Targacept, Inc. Methods and compositions for treatment of central nervous system disorders
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US20030162770A1 (en) 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
BR0309342A (pt) * 2002-04-18 2005-02-15 Astrazeneca Ab Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
MXPA04010190A (es) * 2002-04-18 2005-02-03 Astrazeneca Ab Compuestos heterociclicos.
BR0309343A (pt) * 2002-04-18 2005-02-15 Astrazeneca Ab Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
EP1558252B1 (en) 2002-08-02 2007-10-10 Merck & Co., Inc. Substituted furo [2,3-b]pyridine derivatives
SE0202598D0 (sv) * 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
ATE378048T1 (de) * 2002-12-06 2007-11-15 The Feinstein Inst Medical Res Hemmung von entzündungen unter verwendungvon alpha-7-rezeptor verbindenden cholinergen agonisten
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
WO2004063201A1 (ja) * 2003-01-08 2004-07-29 Mitsubishi Pharma Corporation 統合失調症治療剤
WO2005000250A2 (en) * 2003-06-24 2005-01-06 Johns Hopkins University Imaging agents and methods of imaging alpha 7-nicotinic cholinergic receptor
JP4792393B2 (ja) 2003-09-25 2011-10-12 アストラゼネカ・アクチエボラーグ リガンド
PT1678172E (pt) 2003-10-15 2010-03-03 Targacept Inc Composições farmacêuticas e métodos para alívio da dor e tratamento de perturbações do sistema nervoso central
KR20060094962A (ko) * 2003-10-21 2006-08-30 아스트라제네카 아베 스피로푸로피리딘 아릴 유도체
US20070191815A1 (en) 2004-09-13 2007-08-16 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
WO2005092308A2 (en) * 2004-03-25 2005-10-06 The Feinstein Institute For Medical Research Neural tourniquet
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
ATE489132T1 (de) 2004-12-27 2010-12-15 The Feinstein Inst Medical Res Behandlung von entzündlichen erkrankungen durch elektrische stimulation des vagus-nervs
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
WO2007024814A1 (en) 2005-08-22 2007-03-01 Targacept, Inc. HETEROARYL-SUBSTiTUTED DIAZATRICYCLOALKANES, METHODS FOR ITS PREPARATION AND USE THEREOF
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
TW200813067A (en) * 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
US20080242688A1 (en) * 2007-03-19 2008-10-02 Astrazeneca Ab Method 741
GB2448224B (en) 2007-04-02 2010-09-01 Parkinson S Inst Solid orally administered pharmaceutical composition for the reduction of side-effects of a dopaminergic agent
WO2009017454A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
WO2009029614A1 (en) 2007-08-27 2009-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
KR101565469B1 (ko) 2007-10-01 2015-11-03 코멘티스, 인코포레이티드 알츠하이머병의 치료를 위한 알파 7 니코틴 아세틸콜린 수용체 리간드로서 퀴누클리딘-4-일메틸 1ｈ-인돌-3-카르복실레이트 유도체
RU2481123C2 (ru) 2008-02-13 2013-05-10 Таргасепт, Инк. Комбинация агонистов альфа 7 никотиновых рецепторов и антипсихотических средств
WO2009146030A1 (en) 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
MY157518A (en) 2008-06-20 2016-06-15 Astrazeneca Ab Dibenzothiazepine derivatives and use thereof
EP2355893B1 (en) 2008-11-18 2013-12-25 Setpoint Medical Corporation Devices for optimizing electrode placement for anti-inflamatory stimulation
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
AU2010258792B2 (en) 2009-06-09 2015-07-02 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
JP6095368B2 (ja) 2009-10-27 2017-03-15 ユセベ ファルマ ソシエテ アノニム 機能改変するＮａｖ１．７抗体
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
EP3636314B1 (en) 2009-12-23 2021-09-08 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
WO2011116282A2 (en) 2010-03-19 2011-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nicotinic acetylcholine receptor agonists
RS54742B1 (sr) 2010-05-17 2016-10-31 Forum Pharmaceuticals Inc Kristalni oblik (r)-7-hlor-n-(hinuklidin-3-il)benzo[b]tiofen-2-karboksamid hidrohlorid monohidrata
WO2012154865A2 (en) 2011-05-09 2012-11-15 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
RU2455306C1 (ru) * 2011-05-19 2012-07-10 Государственное образовательное учреждение высшего профессионального образования "Российский университет дружбы народов" (РУДН) СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНЫХ 3',4',5,6-ТЕТРАГИДРО-1Н-СПИРО[ПИРИДИН-4,5'-ТИЕНО[2,3-d]ПИРИМИДИНОВ]
RU2014103098A (ru) 2011-06-30 2015-08-10 Торэй Индастриз, Инк. Противозудный агент
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
WO2013169646A1 (en) 2012-05-08 2013-11-14 Envivo Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
ES2694299T3 (es) 2013-02-07 2018-12-19 Heptares Therapeutics Limited Carboxilatos de piperidin-1-ilo y azepin-1-ilo como agonistas del receptor muscarínico M4
US8893339B2 (en) 2013-03-14 2014-11-25 Select Comfort Corporation System and method for adjusting settings of a bed with a remote control
WO2014202999A1 (en) 2013-06-21 2014-12-24 Takeda Cambridge Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
TW201617342A (zh) 2014-07-11 2016-05-16 阿法馬根公司 調節α７活性之啶類
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
EP3405107B1 (en) 2016-01-20 2023-04-12 Setpoint Medical Corporation Control of vagal stimulation
US10314501B2 (en) 2016-01-20 2019-06-11 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
EP3565617A1 (en) 2017-01-06 2019-11-13 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
AU2019279884A1 (en) 2018-05-29 2020-12-10 Morningside Venture Investments Limited Drug delivery methods and systems
WO2020064655A1 (en) 2018-09-24 2020-04-02 Astrazeneca Ab Azd0328 dosage regime for treating cognitive impairment
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
KR20230012585A (ko) 2020-05-21 2023-01-26 더 파인스타인 인스티튜츠 포 메디칼 리서치 미주 신경 자극을 위한 시스템들 및 방법들
CN115340736B (zh) * 2022-05-20 2023-09-29 扬州实嘉电缆材料有限公司 一种氮磷阻燃剂改性聚氯乙烯防火电缆料

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3681363A (en) * 1970-08-20 1972-08-01 Univ Temple Spiro(imidazolidine-4,3{40 -quinuclidine)-2,5-diones
PL183933B1 (pl) * 1994-08-24 2002-08-30 Astra Ab Związki spiroazabicyklo, sposób wytwarzania związku spiroazabicyklo i kompozycja farmaceutyczna
US5468875A (en) * 1994-12-22 1995-11-21 American Home Products Corporation 1-azabicycloheptane derivatives
DK0842178T3 (da) * 1995-07-28 2001-08-06 Abbott Lab Furopyridin, thienopyridin, pyrrolopyridin og beslægtede pyrimidin-, pyridazin- og triazinforbindelser, som er nyttige til regulering af kemisk synaptisk transmission
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis

Also Published As

Publication number Publication date
NO325324B1 (no) 2008-03-31
DE69827977D1 (de) 2005-01-05
DE69827977T2 (de) 2005-12-08
HUP0003844A3 (en) 2002-11-28
CN1117755C (zh) 2003-08-13
DK0996622T3 (da) 2002-12-30
EP0996622A1 (en) 2000-05-03
IS5338A (is) 2000-01-13
NO20000226L (no) 2000-03-14
HK1046274A1 (en) 2003-01-03
US20020187994A1 (en) 2002-12-12
SI0996622T1 (en) 2003-04-30
HK1025322A1 (en) 2000-11-10
IL134086A (en) 2007-08-19
WO1999003859A1 (en) 1999-01-28
SK183599A3 (en) 2000-08-14
ES2231599T3 (es) 2005-05-16
MY116761A (en) 2004-03-31
ES2185185T3 (es) 2003-04-16
PL193065B1 (pl) 2007-01-31
EP1213291A1 (en) 2002-06-12
CN1270592A (zh) 2000-10-18
NO20000226D0 (no) 2000-01-17
US6369224B1 (en) 2002-04-09
IS2027B (is) 2005-08-15
HUP0003844A2 (hu) 2001-07-30
AU739022B2 (en) 2001-10-04
KR20010021961A (zh) 2001-03-15
EP1213291B1 (en) 2004-12-01
DE69808631T2 (de) 2003-06-12
DE69808631D1 (de) 2002-11-14
US6703502B2 (en) 2004-03-09
EE200000031A (et) 2000-10-16
CA2296031C (en) 2008-01-08
IS2434B (is) 2008-10-15
SA98190668B1 (ar) 2006-09-25
AR013184A1 (es) 2000-12-13
PL338259A1 (en) 2000-10-09
HK1046274B (zh) 2005-05-20
HK1031382A1 (en) 2001-06-15
ATE225792T1 (de) 2002-10-15
TR200000129T2 (tr) 2000-07-21
ID25548A (id) 2000-10-12
JP2001510194A (ja) 2001-07-31
IL134086A0 (en) 2001-04-30
KR100560036B1 (ko) 2006-03-13
US7507744B2 (en) 2009-03-24
EP0996622B1 (en) 2002-10-09
US6110914A (en) 2000-08-29
AR068013A2 (es) 2009-10-28
RU2202553C2 (ru) 2003-04-20
EE04399B1 (et) 2004-12-15
IS7747A (is) 2005-03-16
AU8367998A (en) 1999-02-10
US20080153864A1 (en) 2008-06-26
US20030166935A1 (en) 2003-09-04
ATE283859T1 (de) 2004-12-15
CA2296031A1 (en) 1999-01-28
US6706878B2 (en) 2004-03-16
BR9810924A (pt) 2000-08-15
NZ502298A (en) 2002-02-01
US20050004099A1 (en) 2005-01-06
PT996622E (pt) 2003-01-31
TW515799B (en) 2003-01-01

Similar Documents

Publication Publication Date Title
EP0996622B1 (en) Novel spiroazabicyclic heterocyclic compounds
EP1147114B1 (en) Novel aralkyl amines of spirofuropyridines useful in therapy
EP1397366A1 (en) Novel ligand for nicotinic acetylcholine receptors useful in therapy
CZ2000175A3 (cs) Nové spiroazabicyklické heterocyklické sloučeniny
MXPA00000461A (en) Novel spiroazabicyclic heterocyclic compounds
UA61964C2 (en) New spiroazabicyclic heterocyclic compounds
MXPA01007162A (en) Novel aralkyl amines of spirofuropyridines useful in therapy

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20090710